We serve Chemical Name:5-(3,5-dichlorophenoxy)furan-2-carboxylic acid CAS:175277-06-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-(3,5-dichlorophenoxy)furan-2-carboxylic acid
CAS.NO:175277-06-2
Synonyms:5-(3,5-Dichlorophenoxy)-2-furoic acid;OR1240;HMS566O01
Molecular Formula:C11H6Cl2O4
Molecular Weight:273.06900
HS Code:2932190090
Physical and Chemical Properties:
Melting point:175ºC
Boiling point:411.9ºC at 760mmHg
Density:1.523g/cm3
Index of Refraction:1.604
PSA:59.67000
Exact Mass:271.96400
LogP:4.07690
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-(3,5-Dichlorophenoxy)-2-furoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,HMS566O01 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,HMS566O01 Use and application,OR1240 technical grade,usp/ep/jp grade.
Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 5-(3,5-dichlorophenoxy)furan-2-carboxylic acid manufacturer Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 5-(3,5-dichlorophenoxy)furan-2-carboxylic acid supplier Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 5-(3,5-dichlorophenoxy)furan-2-carboxylic acid vendor Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 5-(3,5-dichlorophenoxy)furan-2-carboxylic acid factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.
